TREXIMET SIDE EFFECTS
- Generic Name: sumatriptan and naproxen sodium tablets
- Brand Name: Treximet
- Drug Class: Antimigraine Agents, NSAIDs
The following serious adverse reactions are described below and elsewhere in labeling:
- Cardiovascular Thrombotic Events
- GI Bleeding, Ulceration and Perforation
- Chest, Throat, Neck, and/or Jaw Pain/Tightness/Pressure
- Cerebrovascular Events
- Other Vasospasm Reactions
- Heart Failure and Edema
- Medication Overuse Headache
- Serotonin Syndrome
- Renal Toxicity and Hyperkalemia
- Anaphylactic Reactions
- Serious Skin Reactions
- Hematological Toxicity
- Exacerbation Asthma Related to Aspirin Sensitivity
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The adverse reactions reported below are specific to the clinical trials with TREXIMET 85/500 mg. See also the full prescribing information for naproxen and sumatriptan products.
Table 1 lists adverse reactions that occurred in 2 placebo-controlled clinical trials (Study 1 and 2) in adult patients who received 1 dose of study drug. Only adverse reactions that occurred at a frequency of 2% or more in any group treated with TREXIMET 85/500 mg and that occurred at a frequency greater than the placebo group are included in Table 1.
Table 1. Adverse Reactions in Pooled Placebo-Controlled Trials in Adult Patients with Migraine
|Adverse Reactions||TREXIMET 85/500 mg
(n = 737)
(n = 752)
|Sumatriptan 85 mg
(n = 735)
(n = 732)
|Nervous system disorders|
|Pain and other pressure sensations|
|Chest discomfort/chest pain||3||<1||2||1|
The incidence of adverse reactions in controlled clinical trials was not affected by gender or age of the patients. There were insufficient data to assess the impact of race on the incidence of adverse reactions.
Pediatric Patients 12 To 17 Years Of Age
In a placebo-controlled clinical trial that evaluated pediatric patients 12 to 17 years of age who received 1 dose of TREXIMET 10/60 mg, 30/180 mg, or 85/500 mg, adverse reactions occurred in 13% of patients who received 10/60 mg, 9% of patients who received 30/180 mg, 13% who received 85/500 mg, and 8% who received placebo. No patients who received TREXIMET experienced adverse reactions leading to withdrawal from the trial. The incidence of adverse reactions in pediatric patients 12 to 17 years of age was comparable across all 3 doses compared with placebo. Table 2 lists adverse reactions that occurred in a placebo-controlled trial in pediatric patients 12 to 17 years of age at a frequency of 2% or more with TREXIMET and were more frequent than the placebo group.
Table 2. Adverse Reactions in a Placebo-Controlled Trial in Pediatric Patients 12 to 17 Years of Age with Migraine
(n = 96)
(n = 97)
(n = 152)
(n = 145)
|Hot flush (i.e., hot flash[es])||0||2||<1||0|
SRC: NLM .